This review of recent literature pertains to the growing evidence that obstructive sleep apnea contributes to the development of systemic hypertension and congestive heart failure.
Introduction
Obstructive sleep apnea (OSA) is a condition that is strongly associated with cardiovascular disease about which detailed reviews have been written [1] [2] [3] . This review summarizes the major publications in the past 12 months.
The importance of OSA diagnosis is highlighted by increased healthcare costs, particularly for cardiovascular diseases, if left untreated. Otake et al. [4] compared the cost of prescribed medications for patients with untreated OSA. Over a 12-month period, patients with untreated OSA incurred $155(Canadian) greater costs for medications per head and had 3.3 more prescriptions, mainly for diuretics, calcium channel blockers, and angiotensin-converting enzyme inhibitors than an agematched control group.
The same group [5] also observed a 25 to 50% greater healthcare usage (physician visits and hospitalizations mainly for systemic hypertension and cardiovascular disease) in the 5 years prior to OSA diagnosis compared with control subjects.
Congestive heart failure
The management of congestive heart failure (CHF) in the past two decades has seen many new and varied therapies. The introduction of vasodilators, angiotensinconverting enzyme inhibitors, ␤ blockers plus biventricular pacing, heart failure centers with nurse practitioners, rehabilitation, artificial mechanical hearts, and transplant have been exciting advances. However, despite such advances, the mortality associated with CHF remains at approximately 50% at 5 years, with only a small improvement in survival in the past 50 years (Fig. 1) [6] .
Congestive heart failure and obesity
The degree to which obesity alone contributes to CHF was reported from the Framingham study analysis of 5881 subjects, in whom a third of the women and half of the men were overweight (body mass index (BMI) 25.0-29.9 kg/m 2 ) and approximately 16% of both sexes were obese (BMI > 30 kg/m 2 ) at baseline [7] . Over a 14-year period 496 subjects (8.4%) developed CHF. Following statistical adjustment for established risk factors (eg, age, cholesterol, cigarette smoking, alcohol consumption, valve disease, hypertension, ECG evidence of left ventricular hypertrophy, and myocardial infarction at baseline), there was a 5 and 7% increase (for males and females respectively) in the risk of CHF with each increment of 1 BMI unit above 25 kg/m 2 . It was estimated that 11% of cases of CHF in men and 14% of CHF in women were attributable to obesity alone. Given the strong relation between obesity and obstructive sleep apnea, this study added credence to the hypothesis that OSA may contribute to the development of CHF.
Obstructive sleep apnea and hypertension
It has been known for more than 15 years that snoring is a risk factor for the development of systemic hypertension. In recent years, carefully conducted rodent and canine studies have confirmed that simulated OSA during sleep leads to elevated daytime awake systemic blood pressure. The effect OSA treatment has on systemic hypertension was unknown until recently.
The first of two recent studies by Pepperell et al. [8] , was a randomized parallel controlled 1-month trial of therapeutic versus subtherapeutic CPAP on 24-hour ambulatory (30 minutely cuff inflation) blood pressure (BP) in patients with OSA, unselected for systemic hypertension. There were 339 eligible patients, of whom 118 were randomized and 95 completed the study. The groups were approximately 50 years of age; BMI was approximately 35 kg/m 2 and BPs approximately 133/85 mm Hg, with 36 SpO2 dips per hour of sleep. CPAP adherence was 4.9 and 4.5 hours per night in the therapeutic and subtherapeutic groups respectively. The mean BP fell from 101.0 ± 9.8 to 98.5 ± 1.2 mm Hg (⌬ 2.5 mm Hg) with CPAP compared with a rise of 0.8 mm Hg (101.7 ± 10.8 to 102.5 ± 1.4 mm Hg) in the control group. A comparison of the differences (3.3 mm Hg fall with CPAP) was highly significant (P = 0.0013). In those patients with severe OSA (4% dip rate > 33/h) the fall in mean BP was greater at 5.1 mm Hg.
The second study by Becker et al. [9••] compared the effects of 9 weeks of therapeutic CPAP with subtherapeutic CPAP on continuous systemic BP in patients with moderate to severe OSA unselected for hypertension. Of 283 subjects assessed, 60 patients were randomized and 32 completed the study with adequate data. The mean ages were approximately 53 years; apnea hypopnea index (AHI) was approximately 63 events per hour and BMI 33 kg/m 2 . Importantly BP was measured continuously and noninvasively with Portapress. This later technical aspect was thought to be responsible for 11 of 28 dropouts. The authors reported a fall in 24-hour mean BP from 100.4 ± 15.9 to 90.6 ± 10.4 mm Hg (⌬ 9.9 mm Hg) whereas the subtherapeutic group had no change (99.5 ± 12.3 to 100.1 ± 9.5 mm Hg). CPAP adherence was 5.5 hours per night.
The disparity of levels of change in systemic BP between these two studies (9.9 vs. 2.5 mm Hg) can be explained by a number of options. First, the method of BP measurement: cuff inflation every 30 minutes over 24 hours, used by Pepperell et al. [8] , would likely induce arousal from sleep and a transient elevation of BP thus blunting or damping a fall in BP with CPAP. In contrast, the study by Becker [9••] used continuous noninvasive BP measurement with plethysmography corrected for the height of the finger; a technique that has been shown not to cause arousal from sleep. Second, the duration of treatment was longer in the Becker [9] study (9 vs. 4 weeks). Third, polysomnography was not performed in the Pepperell study [8] , thus allowing for a possibly greater denominator and lower AHI. Finally, CPAP adherence with CPAP was greater in the Becker study [9] (5.5 hours vs. 4.9 hours)
Obstructive sleep apnea and heart failure
Whether OSA contributes to the development of CHF is not known. In recent years, CHF (excluding viral, valvular, arrhythmic, congenital, and drug-induced cardiomyopathies) has been divided into diastolic and systolic heart failure. Diastolic heart failure is the cause of approximately 50% of acute cardiogenic pulmonary edema whereas 50% is due to systolic heart failure. Diastolic dysfunction is due to the inability of the left ventricle (LV) to relax and fill during diastole, and is commonly caused by tachycardia, hypoxia, and LV hypertrophy. Diastolic dysfunction is often diagnosed by delayed LV relaxation on echocardiogram.
Systolic dysfunction is an inability to contract and is diagnosed by echocardiogram or by nuclear gated blood pool scan. With this framework in mind, evidence over the past 12 months indicates that OSA is a likely cause of both types of CHF.
It is known that LV hypertrophy is associated with a 10-fold risk of developing CHF according to the Framingham study. Fung et al. [10] identified echocardiographic evidence of diastolic dysfunction in 37% of 68 patients with OSA (aged 53 years, BMI 29.1 kg/m 2 , AHI 46/h, and minimum SpO 2 88%). Using multivariate analysis, total sleep time with SaO 2 less than 70% was an independent predictor of diastolic dysfunction with age, hypertension included.
In 28 children (mean age 8 years, BMI 24 kg/m 2 , mean BP 112/58 mm Hg) with polysomnographic-proven OSA, Amin et al. [11] reported greater LV mass on echocardiogram compared with 19 children with primary snoring (mean age 10, BMI 22 kg/m 2 , mean BP 110/57 mm Hg). The degree of LV hypertrophy correlated significantly with the severity of OSA and not with BMI.
In adults with OSA, Alchanatis et al. [12] reported a significantly reduced LVEF (53 ± 7% vs. 61 ± 6%) and lower LV emptying and filling rates suggesting both systolic and diastolic dysfunction compared with healthy controls. Eighteen of the 29 OSA patients (62%) had an LVEF of less than 55% compared with 1 of 12 controls. With 6 months CPAP, the LVEF rose from 53 ± 7% to 56 ± 6% (P < 0.001) with significant improvements in the LV emptying and filling rates. Laaban et al.
[13] also reported 7.7% of 169 unselected patients with OSA to have LVEF less than 50% and a rise in LVEF (44 to 62%) with OSA treatment (6 with CPAP, 1 with palatoplasty) over approximately 12 months.
A major milestone was reached recently with the publication of the first randomized controlled trial of CPAP in 24 subjects with OSA (and < 50% of events being CSA) and ischemic or idiopathic dilated CHF [14••]. Compared with an untreated control group, the CPAP-treated group had a significant improvement in LVEF (25 to 34%) associated with a fall in systolic BP (126 to 116 mm Hg) and a reduction in LV chamber size over 1 month (Fig. 2 ).
Central sleep apnea and heart failure
About 20 to 30% of patients with CHF may exhibit nonhypercapnic central sleep apnea (CSA) with a Cheyne-Stokes pattern of respiration. Such patients have a central apnea followed by a crescendo then decrescendo pattern of ventilation. Characteristically an arousal or state change triggers CSA and an arousal occurs at the peak of ventilation. In addition, CSA occurs mainly in the lighter levels of sleep (stages one and two nonREM) and is associated with hyperventilation and hypocapnia. Such patients usually have elevated pulmonary capillary wedge pressures, lower LVEF, and elevated overnight urinary and awake plasma norepinephrine levels. CSA carries with it a greater mortality.
An elevated peripheral and central ventilatory response at rest in patients with CHF and CSA has been shown in previous reports. Xie et al. [15••] assessed whether the amount of change in ventilation, thus end-tidal CO 2 , was an important factor in differentiating CHF patients with CSA from those without CSA. Using face-mask ventilation during sleep in a group of patients with CHF, endtidal CO 2 values were artificially lowered from eupneic CO 2 to levels sufficient to cause either an apnea (apneic CO 2 threshold) or a hypopnea (hypopneic CO 2 threshold). They observed that central apneas could be induced in CHF patients without CSA; however a greater reduction in end-tidal CO 2 from eupneic to apneic CO 2 (5.1 mm Hg) was required. Conversely, a significantly smaller reduction in the CO 2 level was sufficient to trigger central apnea (2.8 mm Hg) in the CHF-CSA group. Moreover, an even smaller reduction in CO 2 (1.7 mm Hg) was required to trigger a central hypopnea (Fig. 3) .
Thus, CSA can be induced to occur in CHF patients with and without spontaneous CSA and depends on the reduction in PaCO 2 from eupneic level to an apneic level. It is also likely to be relevant in patients with idiopathic CSA patients (who by definition are free of cardiac or neurologic disease) and in those normal subjects who develop periodic breathing at high altitude. In the former, heightened chemosensitivity is observed, but of unknown cause; in particular it is not due to diastolic dysfunction or raised pulmonary vascular pressures [16] . In the latter, hypobaric hypoxia is thought to stimulate ventilation thus driving CO 2 levels below the apneic threshold.
Central sleep apnea and autonomic control
There is compelling evidence that autonomic control is significantly deranged in CSA particularly in the presence of CHF. Using the heart rate variability technique In a further study, Lanfranchi et al.
[18] used heart rate variability (time domain only) in CHF subjects to describe a loss of vagal activity markers (> percent of 50millisecond differences in adjacent RR intervals) in patients with severe CSA compared with CHF patients without CSA. More importantly, they described significantly greater isolated premature ventricular ectopic beats and runs of nonsustained ventricular tachycardia in the patients with severe CSA (AHI > 30/h) compared with those CHF patients without CSA (AHI < 15/h).
These findings support the hypothesis that CSA is a predictor of mortality in CHF. Mechanisms proposed are increased SNA [19•, 20•, 21] . Alternatively endothein-1 [22], a vasoactive peptide that acts to vasoconstrict, is arrhythmogenic, correlates with mortality, and acts synergistically with SNA, has been reported to be elevated in CHF-CSA patients.
Mechanisms responsible for the development of increased ventilatory responses, hyperventilation, and hypocapnia in CHF sufficient to cause CSA are yet to be clarified. Hypoxia is an unlikely cause of CSA in CHF, given that CSA occurs without hypoxemia and that oxy-gen does not completely abolish CSA. Also, arousals are unlikely to be solely responsible for CSA, as CSA can occur during wakefulness (∼5% of patients) [20•]. An elevated sympathetic activity has been postulated to cause the secondary heightened ventilatory response to CO 2 and was supported by Solin et al. [19•] who assessed the overnight urinary norepinephrine excretion (UNE) in 120 subjects: 15 healthy normal, 15 with OSA, and 90 with CHF. The UNE levels rose step-wise from 13.4 to 19.7 to 32.2 nmol norepinephrine/mmol creatinine respectively, suggesting that CHF has a much greater impact on SNA than OSA. Secondly, they reported UNE to be significantly greater in the CHF-CSA group compared with the CHF-OSA and CHF-N groups (43.9 vs. 24.0 vs. 22.4 nmol/mmol creatinine respectively) suggesting that the CHF-CSA group has extraordinarily high SNA activity even greater than that seen with the CHF-OSA group. Moreover, the variance contributing to elevated UNE in the CHF population was explained more so by CHF severity (pulmonary capillary wedge pressure) and to a lesser extent by the degree of hypoxemia.
A further study [20•] reported elevations in awake cardiac and total body SNA in the CHF-CSA group compared with the CHF-OSA and CHF-N groups using the radioactive-labeled norepinephrine spillover technique. Thus, it would appear that CHF has a greater effect on SNA, than does OSA per se, and that the elevated ventilatory responses are likely to be due to severity CHF.
Management of central sleep apnea in congestive heart failure
Effective and practical therapies for CHF-CSA include improved medical therapy directed at the CHF (although prospective controlled data are lacking), positive airway pressure (PAP), and supplemental oxygen.
Kohlein et al.
[23] conducted a randomized controlled trial of either 2 weeks CPAP (∼8.5 mbar) or bilevel PAP (8.5/3 mbar with back-up respiratory rate 15/min) in 16 CHF patients with CSA (mean age 62 years, BMI 27.3, LVEF 23.6%, and AHI 27/hr). Similar improvements were noted with both CPAP and bilevel PAP in terms of fall in percentage of sleep time with CSA (∼37 to 14%), fall in AHI (∼27 to 7 events per hour), arousal frequency (∼31 to 16), and circulation time (∼36 to 30 seconds). Limitations of the study were the absence of an untreated control group, lack of objective cardiac function, and brief study period (2 weeks); nevertheless full polysomnography was performed and their findings support the other studies showing cardiac benefit with CPAP.
The mechanisms by which CPAP works in CSA and CHF is thought to be via reducing transmural pressure gradient, cardiac work, and sympathetic activity [24], reducing left ventricular dimensions, assisting inspiratory muscles (and thus reducing work of breathing), increasing end-expiratory lung volume, and possibly overcoming "cardiac asthma" via broncholdilatation. Krachman et al. [25] assessed the acute effects of approximately 9 cm H 2 O CPAP in 9 patients with CHF and CSA (LVEF 20%, PCWP 20 mm Hg, AHI 44/hr). Singlenight CPAP was associated with a fall in AHI from 44 to 15 per hour, a rise in minimum SpO 2 (87 to 91%), and importantly a fall in the change in SpO 2 with time (dSaO 2 /dt). Thus, the authors confirmed the role CPAP plays in acutely increasing oxygen stores, presumably by increasing lung volumes.
Whether supplemental oxygen has a role to play in CHF-CSA remains to be determined. Some groups have reported that additional oxygen is associated with a fall in cardiac output and a rise in PCWP in patients with CHF [26, 27] . To date, there have been no controlled trials that have shown oxygen to augment cardiac function and thereby reduce severity CSA. Oxygen may reduce CSA directly through elevation of PaCO 2 (Haldane effect) and blunting of chemoreceptors, but whether cardiac function improves in parallel has not been shown.
Andreas et al. [21] , who have previously shown that supplemental oxygen reduces severity of CSA and makes a small increment in VO 2 peak, reported that 3 lpm oxygen had no effect on skeletal muscle activity in awake patients with CHF (unselected for apnea). When asked to perform voluntary breath holds (apneas) the normal rise in skeletal muscle sympathetic nerve activity (MSNA) was attenuated with supplemental oxygen. Limitations of the study were that only one marker of MSNA fell with oxygen (bursts/min and not bursts/100 heart beats), the study was performed during wakefulness, and the apneas were voluntary. Using skeletal muscle microneurography, Andreas et al. confirmed that CHF was associated with double the sympathetic activity compared with normal healthy controls.
A novel therapy reported by Garrigue et al. [28•] was to use atrial pacing to treat sleep apnea. The authors performed two polysomnographs on patients with dualchamber pacemakers in whom LVEF ranged from 40 to 56%: one night with a trial lead disabled (ventricular rate 40 bpm) and the other night with it enabled. Pacemakers had been inserted originally for either sinus node disease or brady-tachy syndrome. Compared with the disabled pacemaker, the enabled pacemaker was associated with a significant rise in mean nocturnal heart rate (51 to 71 bpm) and a fall in overall AHI (∼28 to 11 /h), central apnea index (∼13 to 6), and less so on the obstructive apnea index (6 to 3/hr). Thus, CSA may be attenuated by correction of rhythm disturbance.
Conclusion
The role of sleep-disordered breathing in cardiovascular disease has strengthened. There is no doubt now that OSA contributes to systemic hypertension and LV diastolic and systolic dysfunction. Randomized trials have now shown the important observations that both hypertension and LV systolic dysfunction improve with CPAP.
• 19 Solin P, Kaye DM, Little PJ, et al.: Impact of sleep apnea on sympathetic activity in heart failure. Chest 2003 Chest , 123:1119 Chest -1126 . This is the first study to compare sympathetic activity (measured by overnight urinary norepinephrine) in normal subjects, patients with OSA, and patients with CHF and varying degrees of CHF. Importantly CHF contributes to sympathetic activity to a greater degree than does OSA. 
